Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$1.39 - $2.21 $62,224 - $98,932
-44,766 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$1.27 - $3.42 $149 - $403
118 Added 0.26%
44,766 $88,000
Q4 2020

Feb 12, 2021

SELL
$0.94 - $1.89 $10 - $20
-11 Reduced 0.02%
44,648 $56,000
Q3 2020

Nov 04, 2020

BUY
$1.5 - $9.38 $6,208 - $38,823
4,139 Added 10.21%
44,659 $80,000
Q2 2020

Aug 12, 2020

BUY
$4.79 - $8.39 $7,405 - $12,970
1,546 Added 3.97%
40,520 $340,000
Q1 2020

May 04, 2020

BUY
$3.44 - $7.21 $6,202 - $12,999
1,803 Added 4.85%
38,974 $204,000
Q4 2019

Feb 05, 2020

SELL
$4.29 - $5.64 $1,334 - $1,754
-311 Reduced 0.83%
37,171 $203,000
Q3 2019

Nov 08, 2019

SELL
$4.87 - $7.08 $1,275 - $1,854
-262 Reduced 0.69%
37,482 $183,000
Q2 2019

Aug 13, 2019

BUY
$6.6 - $7.8 $18,975 - $22,425
2,875 Added 8.25%
37,744 $262,000
Q1 2019

May 06, 2019

BUY
$5.76 - $8.95 $11,681 - $18,150
2,028 Added 6.18%
34,869 $242,000
Q4 2018

Feb 13, 2019

SELL
$5.26 - $7.97 $1,325 - $2,008
-252 Reduced 0.76%
32,841 $192,000
Q3 2018

Nov 09, 2018

BUY
$4.65 - $7.95 $2,771 - $4,738
596 Added 1.83%
33,093 $250,000
Q2 2018

Aug 08, 2018

BUY
$5.05 - $6.8 $5,560 - $7,486
1,101 Added 3.51%
32,497 $164,000
Q1 2018

May 07, 2018

SELL
$5.6 - $9.25 $7,022 - $11,599
-1,254 Reduced 3.84%
31,396 $192,000
Q4 2017

Feb 09, 2018

BUY
$6.6 - $7.78 $19,509 - $22,997
2,956 Added 9.95%
32,650 $232,000
Q3 2017

Nov 09, 2017

BUY
$5.75 - $7.75 $170,740 - $230,128
29,694
29,694 $212,000

Others Institutions Holding CRBP

About Corbus Pharmaceuticals Holdings, Inc.


  • Ticker CRBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,268,000
  • Market Cap $1.63B
  • Description
  • Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
More about CRBP
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.